Company: Memory Pharmaceuticals [1]
Starting stock price: $2.69
Ending stock price: $0.56
Percent Change: -79.18%
Details: In March of 2007, Memory's stock took a hit after researchers announced that its lead drug--MEM 1003--failed to achieve any of its endpoints in a mid-stage study for mania in bipolar patients. Results of the same drug as a therapy for Alzheimer's were no better, and the company's stock suffered another major hit in October when MEM 1003 fell short in demonstrating a statistically significant response for improved symptoms after 12 weeks. Â
More News:
Memory's Alzheimer's drug aces Phase II. Report [2]
Memory's Alzheimer's drug flunks Phase II. Report [3]
Memory shares plunge as lead drug fails trial. Report [4]
Links:
[1] http://www.memorypharma.com/
[2] http://www.fiercebiotech.com/story/memorys-alzheimers-drug-aces-phase-ii/2007-11-02
[3] http://www.fiercebiotech.com/story/memorys-alzheimers-drug-flunks-phase-ii/2007-10-15
[4] http://www.fiercebiotech.com/story/memory-shares-plunge-as-lead-drug-fails-trial/2007-03-05
[5] http://www.fiercepharma.com/special-reports/cytogen-worst-pharma-stocks-2007
[6] http://www.fiercepharma.com/special-reports/worst-pharma-stocks-2007
[7] http://www.fiercepharma.com/special-reports/interpharm-worst-pharma-stocks-2007